JP2020075868A - Volatilization promotion method of trans-fluthrin, trans-fluthrin volatilization promoter and agent volatilization composition - Google Patents

Abstract

To provide a volatilization promotion method of trans-fluthrin, capable of enhancing volatilization amount of trans-fluthrin at an ordinary temperature, and exhibiting evasion effect on pest insect from initial use.SOLUTION: The above described problem is solved by blending at least one or more kind of pyrethroidal compound selected from a group consisting of pyrethroidal compounds having vapor pressure at 25°C of 1.0×10Pa to 1.3×10Pa with an agent volatilization composition containing trans-fluthrin.SELECTED DRAWING: Figure 1

Description

  TECHNICAL FIELD The present invention relates to a method for promoting volatilization of transfluthrin, a transfluthrin volatilization accelerator, and a chemical volatilization composition.

  2. Description of the Related Art In recent years, a technique is known in which a drug volatilizer in which a room temperature volatilizable drug is held on a carrier is installed indoors or outdoors, and the drug is continuously volatilized in a space to avoid pests. As the room temperature volatile drug, transfluthrin is widely used, as described in Patent Documents 1 and 2, for example. Transfluthrin is a pest-controlling component of pyrethroid compounds and has high insecticidal activity against agricultural pests such as leafhoppers and aphids, sanitary pests such as mites and cockroaches, and repellent efficacy against certain pests. It has been investigated as an active ingredient of various preparations especially for sanitary pests, because of its high safety. On the other hand, Patent Document 3 discloses a technique in which the shape of a container accommodating a room temperature volatile drug is specified, air is easily introduced into the container, and volatilization of the room temperature volatile drug is promoted.

JP, 2008-194034, A JP 2001-192309 A JP, 2008-93778, A

However, there is a problem that transfluthrin has a low vapor pressure in order to be vaporized at room temperature, and that it takes a considerable amount of time to obtain the amount of vaporized until it has a repellent effect against flying insects.
Therefore, an object of the present invention is to increase the amount of transfluthrin volatilized at room temperature and to exert a repellent effect against pests from the beginning of use, a method for promoting transfluthrin volatilization, a transfluthrin volatilization accelerator, and a chemical volatilization composition. To provide things.

As a result of intensive studies, the present inventors have found that the combined use of transfluthrin and a pyrethroid compound having a vapor pressure in a specific range can increase the volatilization amount of transfluthrin at room temperature, and the present invention It came to completion.
That is, the present invention is as follows.

1. At least one selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa or more and 1.3 × 10 ⁻² Pa or less in a drug volatilization composition containing transfluthrin. A method for promoting volatilization of transfluthrin, which comprises blending the above pyrethroid compound.
2. Furthermore, promotion of volatilization of transfluthrin according to 1 above, containing at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of higher than 1.3 × 10 ⁻² Pa. Method.
A transformer containing at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure of 1.0 × 10 ⁻³ Pa or more and 1.3 × 10 ⁻² Pa or less at 3.25 ° C. Fluthrin volatilization accelerator.
4. Furthermore, the transfluthrin volatilization accelerator according to the above 3, further comprising at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of higher than 1.3 × 10 ⁻² Pa. ..
5. Transfluthrin and at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa or more and 1.3 × 10 ⁻² Pa or less. , At least one pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of greater than 1.3 × 10 ⁻² Pa, for promoting volatilization of transfluthrin. , A drug volatilization composition.

The method for promoting volatilization of transfluthrin of the present invention is a pyrethroid in which a chemical volatilization composition containing transfluthrin has a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa to 1.3 × 10 ⁻² Pa. It is characterized in that at least one pyrethroid compound selected from the group consisting of compounds (hereinafter sometimes referred to as the first pyrethroid compound) is blended. According to this configuration, the first pyrethroid compound can increase the amount of transfluthrin volatilized at room temperature, particularly the amount volatilized at the beginning of use, and it is possible to exert a repellent effect against pests from the beginning of use. Become.

Further, in addition to the first pyrethroid compound, at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of higher than 1.3 × 10 ⁻² Pa (hereinafter, referred to as a first pyrethroid compound). 2) may be referred to as a pyrethroid compound), the amount of transfluthrin volatilized at room temperature, particularly the amount of volatilized at the beginning of use, can be remarkably increased, and repellent against pests from the beginning of use can be avoided. The efficacy can be further enhanced.

  Further, the transfluthrin volatilization accelerator of the present invention is characterized by containing a first pyrethroid compound. According to this configuration, the volatilization amount of transfluthrin at room temperature, particularly the volatilization amount at the beginning of use, can be significantly increased, and the pest repellent effect from the beginning of use can be further enhanced.

  Further, in the transfluthrin volatilization accelerator of the present invention, in addition to the first pyrethroid compound, in addition to the second pyrethroid compound, the amount of transfluthrin volatilized at room temperature, especially at the initial stage of use, The amount of volatilization can be remarkably increased, and the repellent effect against harmful insects from the early stage of use can be further enhanced.

  The drug volatilization composition of the present invention is characterized by containing transfluthrin, a first pyrethroid compound, and a second pyrethroid compound. According to this configuration, the first pyrethroid compound and the second pyrethroid compound can significantly increase the volatilization amount of transfluthrin at room temperature, particularly the volatilization amount at the beginning of use, and repel pests from the beginning of use. It becomes possible to exert the effect.

It is a figure for explaining an example of a medicine volatilization device to which a method for promoting volatilization of transfluthrin of the present invention can be applied. It is sectional drawing of the chemical volatilization apparatus of FIG. FIG. 3 is a diagram for explaining a test device used in Test Example 1. It is a figure for demonstrating the test device used in the test example 2 and the test example 3.

Hereinafter, embodiments of the present invention will be described in more detail.
The method for promoting transfluthrin volatilization of the present invention is a pyrethroid system in which a vaporized composition containing transfluthrin has a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa to 1.3 × 10 ⁻² Pa. At least one or more pyrethroid compounds selected from the group consisting of compounds (hereinafter, also referred to as a first pyrethroid compound) is blended.
Further, the transfluthrin volatilization accelerator of the present invention is characterized by containing a first pyrethroid compound.

Transfluthrin has the following structure, has a vapor pressure of 1.0 × 10 ⁻³ Pa at 25 ° C., and has a low vapor pressure to be vaporized at room temperature as described above. There is a problem that it takes a considerable amount of time to obtain the amount of volatilization until it becomes effective.

In the present invention, the above-mentioned problems are solved by using transfluthrin and the first pyrethroid compound in combination.
The first pyrethroid compound is at least one pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa or more and 1.3 × 10 ⁻² Pa or less. Examples of the compound include profluthrin (vapor pressure at 25 ° C. = 1.0 × 10 ⁻² Pa) and metfluthrin (vapor pressure at 25 ° C. = 1.9 × 10 ⁻³ Pa). The first pyrethroid compound does not include transfluthrin.
If the vapor pressure of the first pyrethroid-based compound at 25 ° C. is less than 1.0 × 10 ⁻³ Pa, the vapor pressure is lower than that of transfluthrin for vaporization at room temperature, and transfluthrin is difficult to vaporize. Not preferable.

  Among them, the first pyrethroid system from the viewpoint that the volatilization amount of transfluthrin at room temperature, particularly the volatilization amount at the beginning of use, can be remarkably increased, and the repellent effect against pests from the beginning of use can be further enhanced. As the compound, profluthrin having the following structure is preferable.

  The ratio of transfluthrin to the first pyrethroid compound used is preferably 1/1 to 1000/1, more preferably 10/1 to 200/1, as the former / latter (mass ratio).

Further, in the present invention, in addition to the first pyrethroid compound, at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of higher than 1.3 × 10 ⁻² Pa ( Hereinafter, a mode in which a second pyrethroid compound is also used together is preferable. According to this mode, the volatilization amount of transfluthrin at room temperature, particularly the volatilization amount at the beginning of use, can be remarkably increased, and the pest repellent effect from the beginning of use can be further enhanced.

Examples of the second pyrethroid-based compound include enpentrin (vapor pressure at 25 ° C. = 1.4 × 10 ⁻² Pa).

  Among them, the second pyrethroid system from the viewpoint that the volatilization amount of transfluthrin at room temperature, particularly the volatilization amount at the beginning of use, can be remarkably increased and the pest repellent effect from the beginning of use can be further enhanced. As the compound, an empentryn having the following structure is preferable.

  The ratio of transfluthrin to the second pyrethroid compound used is preferably 1/1 to 1000/1, more preferably 2.5 / 1 to 20/1, as the former / latter (mass ratio).

FIG. 1 is a diagram for explaining an example of a drug volatilization device to which the method for promoting volatilization of transfluthrin of the present invention can be applied.
The drug volatilization apparatus 1 is used indoors or outdoors by suspending a container 3 containing a carrier 2 holding a drug volatilization composition containing transfluthrin from above with a hanging hook 5. A plurality of ventilation openings 4 are formed on the front surface of the container 3, and a plurality of ventilation openings 4 ′ are also formed on the back surface thereof (see FIG. 2).

As shown in FIG. 2, the container 3 is a substantially plate-shaped body having a front surface portion 3a and a rear surface portion 3b. In the present invention, the front surface of the container 3 refers to the outer surface of the front portion 3a, and the back surface of the container 3 refers to the outer surface of the back portion 3b.
The front surface portion 3a and the rear surface portion 3b are integrated with each other at least at their side edge portions, and a space 6 for ventilation is formed therein. The ventilation openings 4 and 4'are provided in the same shape and at the same position on the front surface 3a and the rear surface 3b so as to maintain air permeability from the front surface to the rear surface of the container 3. By providing such ventilation openings 4 and 4 ′, transfluthrin in the drug vaporization composition retained on the carrier 2 can be vaporized from the ventilation openings 4 and 4 ′.
The shape and formation position of the ventilation openings 4 and 4'are not particularly limited as long as air permeability is secured between the front surface portion 3a and the rear surface portion 3b and transfluthrin can be efficiently volatilized. It can be designed in a shape or position, for example, it may be provided on the side surface of the container 3, but in order to increase the amount of transfluthrin volatilized, the total area of the ventilation openings 4, 4 ′ relative to the surface area of the container 3 is The larger the ratio, the better.

The container 3 is formed by separately forming the front surface portion 3a and the rear surface portion 3b at least at the side edge portions or by abutting them, but they may be integrally formed. The front part 3a and the back part 3b are provided with a plurality of clamping members 8a and 8b on their inner surfaces, and the clamping members 8a and 8b are abutted against each other while the carrier 2 is clamped between them to be integrated. To be done.
The material forming the container 3 (the front surface portion 3a and the rear surface portion 3b) is not particularly limited, and can be formed of, for example, various types of plastic, metal, glass, paper, wood, ceramics and the like.

  The front part 3a and the back part 3b can be integrated by, for example, a method using a locking member, a method by heat fusion, a method using an adhesive or the like. Examples of the method using the locking member include a method in which a not-shown claw portion is provided on one of the peripheral edge portions of the front surface portion 3a and the back surface portion 3b, and a concave portion is provided at the other, and the claw portion is locked in the concave portion. . The front surface portion 3a and the rear surface portion 3b may be detachably integrated with each other by using the above-mentioned locking member.

  Examples of the carrier that holds the drug volatilization composition include a net formed from a fiber material. This net has openings that serve as ventilation holes that are useful for vaporizing transfluthrin. Specifically, it is possible to use a yarn that is knitted by using a method such as lace knitting or knitting using a yarn of a short fiber or a long fiber.

Examples of the material of the short fiber or long fiber thread include natural fibers such as pulp, cotton, wool, hemp, and silk, polypropylene, polyethylene, polyamide, polyethylene terephthalate, polybutylene terephthalate, polysulfone, rayon, and methacrylic acid resin. Other examples include biodegradable resins (polyglycolic acid, polylactic acid, poly (β-hydroxybutyric acid)) and the like, and one kind or a mixture of two or more kinds of these materials can be used. Among these, polyethylene terephthalate, polypropylene, polybutylene terephthalate, and polyethylene are particularly preferable.
The fibers may contain conventionally known additives such as antifungal agents, dyes, ultraviolet absorbers, and fragrances.

  The ratio of openings (ventilation holes) of the net is not particularly limited, but the ratio of the total area of the openings to the total area of the net (opening ratio) is 5 to 80%, preferably 10 to 50%. Is good. If the opening ratio is too small, the volatility of the transfluthrin retained on the yarn may decrease, while if the opening ratio is too large, the weight of the yarn per unit area (that is, the basis weight) decreases, and The retention amount of the volatilization composition tends to decrease.

  The method of holding the drug volatilizing composition on the carrier is not particularly limited, and for example, a method of preparing a solution of the drug volatilizing composition, immersing the carrier (net) in the solution, and impregnating the drug volatilizing composition, or A method of impregnating the drug or the drug volatilizing composition itself onto the net by spraying or dropping it onto the net, a method of kneading the drug into a carrier, or the like can be adopted. Further, if necessary, the solvent used may be removed by impregnation with the drug volatilization composition and then drying. Further, each of the above operations for holding the drug volatilization composition can be repeated until the amount of transfluthrin retained reaches a desired amount.

The amount of transfluthrin retained on the carrier is preferably 0.01 g or more and 10 g or less, and more preferably 0.1 g or more and 5 g or less, from the viewpoint of exerting repellent effect against pests from the initial stage of use.
Further, the amount of the first pyrethroid compound retained on the carrier is preferably 0.00001 g or more and 10 g or less, and more preferably 0.0005 g or more and 0.5 g or less, from the viewpoint of promoting volatilization of transfluthrin.
The amount of the second pyrethroid compound retained on the carrier is preferably 0.00001 g or more and 10 g or less, more preferably 0.005 g or more and 2 g or less, from the viewpoint of further promoting the volatilization of transfluthrin.

The size of the carrier is not particularly limited, but is preferably 10 to 1000 cm ² , and more preferably 20 to 500 cm ² .

  The carrier 2 may be held by a frame (not shown). If the frame holding the carrier 2 is made into a cartridge type, when the room temperature volatile drug is completely or almost completely vaporized and the efficacy disappears or decreases, the frame after use is replaced with a new frame. Thus, the excellent effect can be expressed again.

  As shown in FIGS. 1 and 2, the container 3 is suspended from a hook-shaped fixture 9 by a suspension hook 5. Further, although the hook-shaped fixture 9 is attached to the ceiling surface or the like, it is not a hook-shaped fixture, and for example, even if the hanging hook 5 is hooked on a clothesline, a balcony, or a handrail of a staircase outdoors. Well, there is no particular limitation. The hanging hook 5 may be a hanging string made of a single string having both ends tied together into a ring shape.

  The drug volatilization apparatus 1 of the present embodiment can be used, for example, by hanging it indoors or outdoors, and at normal temperature, transfluthrin volatilizes with a sufficient volatilization amount from the beginning of use, for example, for mosquitoes, flies and the like. It is effective to control harmful insects if they are hung from the entrances and openings of buildings where the flying insects invade.

  The drug volatilization composition of the present invention may contain other components in addition to transfluthrin, the first pyrethroid compound and the second pyrethroid compound, if necessary. Examples thereof include other insect pest control agents other than the above-mentioned transfluthrin, the first pyrethroid compound and the second pyrethroid compound, aromatic agents, deodorants / deodorants, bactericides, antifungal agents and the like.

  Other pest control agents include, for example, various organic phosphorus-based and carbamate-based insecticides, repellents, insect growth regulators, and the like. Examples of pest control agents include DDVP, diazinon and the like as organophosphorus insecticides, and propoxur and the like as carbamate insecticides. In addition, plant essential oils, terpenes, and their isomers and derivatives can also be used as other pest control agents.

  As the fragrance, for example, lavender oil, musk, dragonfly, abies oil, citronella oil, eucalyptus oil, fennel oil, garlic oil, ginger oil, grapefruit oil, lemon oil, lemongrass oil, nutmeg oil, peppermint oil. , Essential oils such as orange oil, turpentine oil, sage oil, pinene, limonene, linalool, geraniol, citronellal, borneol, benzyl alcohol, anis alcohol, anethole, eugenol, aldehyde, citral, citronellal, vanillin, carvone, ketone, menthone, acetophenone , Coumarin, cineol, ethyl acetate, octyl acetate, linalyl acetate, butyl cyclohexyl acetate, butyl cycloheptyl acetate, isopropyl isobutyrate, allyl caproate, ethyl benzoate, methyl cinnamate, methyl salicylate and the like.

  Examples of deodorants / deodorants include benzyl acetate, benzyl propionate, amylcinnamic aldehyde, anisic aldehyde, diphenyl oxide, methyl benzoate, ethyl benzoate, methyl phenylacetate, ethyl phenylacetate, neoline, safrole, citronella. Oil, lemongrass oil and the like can be mentioned.

  Examples of the bactericides include IPMP (isopropylmethylphenol), PCMX (p-chloro-m-xylenol), AIT (allyl isothiocyanate), hinokitiol, and stabilized chlorine dioxide.

  Further, the drug volatilizing composition in the present invention may contain a solvent for preparing a solution of a drug capable of volatilizing at room temperature. The solvent is not particularly limited, for example, water, naphthenes, kerosene, hydrocarbons such as paraffin, glycerin, propylene glycol, dipropylene glycol, hexylene glycol, methanol, isopropanol, 1-octanol, 1-dodecanol, etc. Alcohols, acetone, ketones such as acetophenone, dihexyl ether, diethylene glycol diethyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monobutyl ether, ethers such as dipropylene glycol dimethyl ether, hexyl laurate, dioctyl adipate, malonic acid Examples thereof include esters such as diethyl and diethyl phthalate, and one or more kinds such as xylene, chlorsene, and silicone oil.

  Furthermore, the drug volatilization composition in the present invention may contain various additives, if necessary, within a range that does not impair the effects of the present invention. Examples of the additive include a potency enhancer, a volatilization rate improver, a stabilizer, an antioxidant, and a dye. The additive may be only one kind or two or more kinds.

Examples of the volatilization rate improver include phenethyl isothiocyanate and dimethyl hymixate.
Examples of the stabilizer include, for example, 3,5-di-t-butyl-4-hydroxytoluene, 3-t-butyl-4-hydroxyanisole, mercaptobenzimidazole, dilauryl-thio-di-propionate and 2,2'-. Methylene-bis- (6-t-butyl-4-methylphenol), 4,4'-methylene-bis- (2,6-di-t-butylphenol), 4,4'-thio-bis- (6- t-butyl-3-methylphenol), phenyl-β-naphthylamine, 2-t-butyl-4-methoxyphenol, stearyl-β- (3,5-di-t-butyl-4-hydroxyphenyl) propionate, α -Tocopherol, ascorbic acid, erythorbic acid and the like.
Examples of the antioxidant include butylhydroxyanisole, dibutylhydroxytoluene, tocopherol, γ-oryzanol, erythorbic acid, sodium erythorbate, propyl gallate and the like.

  Hereinafter, the present invention will be further described with reference to examples, but the present invention is not limited to the following examples. In the following examples, the test environment was 30 ° C.

Test example 1
According to the formulation shown in Tables 1 and 2 below, the drug volatilization compositions 1 to 7 containing transfluthrin were prepared. The drug volatilization compositions 2, 3, 5, and 6 correspond to Examples, and the drug volatilization compositions 1, 4, and 7 correspond to Comparative Examples.

  Various components were impregnated into the carrier 2 by instilling the prepared drug volatilization compositions 1 to 7 onto the carrier 2 in the drug volatilization apparatus 1 shown in FIGS. 1 and 2, to obtain specimens 1 to 7, respectively. As the carrier 2, a net-shaped polyester carrier having a length of 14 cm, a width of 9 cm, and an opening ratio of 15% was used.

Next, as shown in FIG. 3 (A), a test apparatus 30 for measuring the volatilization amount of various pyrethroid compounds was prepared. The test apparatus 30 is made of a plastic box 31 (a cube having a side length of 1 m), and intake holes 32 are provided at two positions on the ceiling surface of the box 31. On the other hand, a fan-equipped exhaust hole 33 is provided at one location on the bottom of the side surface of the box 31. The exhaust holes 33 are provided so that the air in the box 31 is exhausted at a rate of 17 L / min and the air in the box 31 is exhausted in approximately one hour.
Subsequently, as shown in FIG. 3B, a small fan 34 was installed in the box 31 to circulate the air in the box 31. Then, the sample 35 was suspended in the substantially central portion of the box 31.

For Samples 1 to 6, the test using the box 31 is continued for 7 days, and the sample 35 is taken out 7 days after the start of the test, each active ingredient contained in the carrier is extracted with acetone, and the carrier is analyzed by a gas chromatograph. The amount of each remaining active ingredient was quantified, and the volatilization amount (mg) of each active ingredient per day from the sample was calculated. Further, for the sample 7, the test using the box 31 was continued for 11 days, and the test was performed in the same manner as the samples 1 to 6 except that the sample 35 was taken out 11 days after the start of the test. The volatilization amount (mg) of each active ingredient per day was calculated.
The results are shown in Table 3. The number of tests (n) for the sample 7 was 3, and the number of tests (n) was 4 for the samples 1 to 6, and the results are shown as average values.

In Table 3, when comparing Samples 1 and 3 (drug volatilization compositions 1 and 3) with Samples 4 and 6 (drug volatilization compositions 4 and 6), respectively, transfluthrin and profluthrin (first pyrethroid compound) It can be seen that the drug volatilization compositions 3 and 6 in which the above are used in combination have a larger amount of transfluthrin volatilized per day in the initial 7 days than the drug volatilization compositions 1 and 4, respectively.
Further, when the drug volatilization compositions 1 and 2 are compared with the drug volatilization compositions 4 and 5, respectively, the drug volatilization in which transfluthrin, profluthrin (first pyrethroid compound) and enpentrin (second pyrethroid compound) are used together It can be seen that the compositions 2 and 5 had a significantly larger amount of transfluthrin vaporized per day in the initial 7 days than the drug volatilization compositions 1 and 4, respectively.

Test example 2
Specimens 1, 2, 4 and 5 prepared in Test Example 1 were used as the drug volatilization composition, and Samples 1, 2, 4 and 5 containing the drug volatilization compositions 1, 2, 4 and 5 were used as in Test Example 1. 5 were produced respectively.
Then, the test apparatus 40 shown in FIG. 4 was produced. In FIG. 4, the test apparatus 40 has a hollow cylindrical shape with a diameter of 20 cm and a length of 100 cm, a specimen 45 is installed at one end (upstream end) 41, and a fan 44 is located 15 cm downstream from the specimen 45. Is installed, and the other end (downstream end) 46 is installed with a mesh-shaped test cage 47 containing 20 test insects (Chironomidae adults (mixed sex)). The test apparatus 40 was set so that air was circulated from the upstream direction to the downstream direction at a wind velocity of 0.1 m / sec by the operation of the fan 44.
After the operation of the fan 44 was started and the test insects were exposed to the volatilized drug, the knockdown number of the test insects was counted every one minute and observed until the total number of the knocked down animals. After that, KT50 (time at which 50% of test insects knocked down: minutes) was calculated by probit regression analysis.
The results are shown in Table 4. The number of tests (n) was twice, and the results are shown as an average value.

  In Table 4, when comparing Samples 1 and 2 (drug volatilizing compositions 1 and 2) with Samples 4 and 5 (drug volatilizing compositions 4 and 5), respectively, transfluthrin and profluthrin (first pyrethroid compound) It can be seen that the drug volatilization compositions 2 and 5 combined with and empentryn (second pyrethroid compound) have shorter time until the test insect knocks down as compared with the drug volatilization compositions 1 and 4, respectively.

Test example 3
According to the formulation shown in Table 5 below, the drug volatilization compositions 8 to 11 containing transfluthrin were prepared, and in the same manner as in Test Example 1, samples 8 to 11 containing the drug volatilization compositions 8 to 11 were prepared. .. The drug volatilization compositions 10 and 11 correspond to Examples, and the drug volatilization compositions 8 and 9 correspond to Comparative Examples.
Subsequently, the test apparatus 40 shown in FIG. 4 was used to carry out a test according to the following procedures (1) to (4), and the blood feeding inhibition rate and the knockdown rate were investigated. 20 adult Aedes albopictus (female) were used as test insects.
(1) Before exposing the test insect to the volatilized drug, the operator's hand was held over the mesh portion (outside) of the test cage 47. Then, for 1 minute, the number of mosquitoes that took the action of puncturing the hands of the practitioner from the inside of the mesh part (action indicating the desire to suck blood) was counted (most test insects showed the desire to suck blood). I confirmed that I took the action shown).
(2) After installing the test cage 47 in the test apparatus 40, the operation of the fan 44 was started, and the test insects were exposed to the vaporized drug for 2 minutes.
(3) The test cage 47 was taken out from the test apparatus 40, the number of knockdowns of the test insects was counted, and the knockdown rate with respect to the total number of cattle was calculated.
(4) The operator's hand was held over the mesh portion (outside) of the test cage 47. Then, for 1 minute, the number of mosquitoes that took the action of sticking a needle into the hand of the practitioner from the inside of the mesh portion (behavior-indicating behavior) was counted.

The blood feeding inhibition rate was calculated by the following formula.
Blood-sucking inhibition rate (%) = {(number of heads showing willingness to suck blood before the start of test-number of heads showing willingness to suck blood after the test) / (number of heads showing willingness to suck blood before the test)} × 100

  Table 6 shows the blood sucking inhibition rate and knockdown rate obtained. The number of tests (n) was twice, and the results are shown as an average value.

  From the results of Test Example 3, comparing Samples 8 and 9 (drug volatilizing compositions 8 and 9) with Samples 10 and 11 (drug volatilizing compositions 10 and 11), transfluthrin and profluthrin (first pyrethroid system) were compared. It can be seen that the drug volatilization composition 11 in which the compound) is used in combination has improved blood-sucking inhibition rate and knockdown rate as compared with the drug volatilization compositions 8 and 9. In addition, the drug volatilization composition 10 in which transfluthrin, profluthrin (first pyrethroid compound) and enpentrin (second pyrethroid compound) were used in combination, compared with the drug volatility compositions 8 and 9, the blood-sucking inhibition rate and knockdown rate. It can be seen that is significantly improved.

1 Chemical Volatilization Device 2 Carrier 3 Container 3a Front Part 3b Back Part 4, 4'Ventilation Opening Part 5 Suspending Hook (Suspending Tool)
6 Spaces 8a, 8b Clamping member 9 Fixture 30 Test device 31 Box 32 Intake hole 33 Exhaust hole 34 Small fan 35 Specimen 40 Test device 41 Upstream end 44 Fan 45 Specimen 46 Downstream end 47 Test cage

Claims (5)

At least one selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa or more and 1.3 × 10 ⁻² Pa or less in a drug volatilization composition containing transfluthrin. A method for promoting volatilization of transfluthrin, which comprises blending the above pyrethroid compound. The volatilization of transfluthrin according to claim 1, further comprising at least one pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of higher than 1.3 × 10 ⁻² Pa. Promotion method. Transfluthrin containing at least one pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa or more and 1.3 × 10 ⁻² Pa or less. Volatilization accelerator. The transfluthrin volatilization promotion according to claim 3, further comprising at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C of higher than 1.3 × 10 ^-2 Pa. Agent. Transfluthrin and at least one or more pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of 1.0 × 10 ⁻³ Pa or more and 1.3 × 10 ⁻² Pa or less. , At least one pyrethroid compound selected from the group consisting of pyrethroid compounds having a vapor pressure at 25 ° C. of greater than 1.3 × 10 ⁻² Pa, for promoting volatilization of transfluthrin. , A drug volatilization composition.

Images